

Panayotis Catsoulacos and Ch. Camoutsis

Department of Chemistry, Nuclear Research Center "Demokritos",
Aghia Paraskevi Attikis, Greece

Laboratory of Pharmaceutical Chemistry,
University of Patras, Greece

Received April 28, 1981


In order to discover new useful steroids in which the cyclopentanoperhydrophenanthrene system is condensed with various heterocyclic rings, many new compounds are continually being synthesized and tested for physiological action. The thiazole, isothiazole, thiazoline and thiazolidine ring condensed on several positions of the steroidal skeleton, has shown great interest due to the physiological properties. Literature coverage for this review includes publications which appear from 1946 to the 1980's.

J. Heterocyclic Chem., 18, 1485 (1981).

Steroido[3,2-*d*]thiazoles.


Compounds of this class, with an H or a CH₃, C₆H₅, OC₂H₅, NH₂, NHC₆H₅, NHCH₂CH=CH₂ and SH substituted at the 2', were synthesized by treatment of the 2 α -bromo-3-ketosteroids (I) with thioformamide (1-5), thioacetamide (1-6), thiobenzamide (1), xanthogenamide (1), thiourea (2-3, 7-10), *N*-phenyl- (2-3), *N*-allylthiourea (2-3) and ammonium dithiocarbamate (11) in alcoholic solution.

The compounds prepared are listed in Table I.



The characteristic specific rotary powers and ultraviolet spectra of the above thiazoles are listed in Tables II and III, respectively.

When the reaction of the 2 α -bromo-3-ketosteroids (III) with thiourea was performed in dimethylformamide the corresponding 2'-formamidothiazolosteroids (IV) were formed, which were converted into 2'-aminothiazolosteroids (V) after hydrolysis with dilute sulfuric acid or alcoholic potassium hydroxide (12).




2'-Formamidothiazolosteroids (IV) also were obtained by the reaction of the 2'-aminothiazolosteroids (V) with dimethylformamide at reflux temperature or with formyl

acetic anhydride at room temperature (12).


Furthermore, the 2'-formamidothiazolosteroids (IVb) on reduction with lithium aluminium hydride produced the 2'-methylaminothiazolosteroids (VI) (12).

The 2',3'-dihydrothiazoles have been prepared by thermal rearrangement of the thioesters, according to the following equation (13).



On treating the 1 α ,2 α -epoxy-3-ketosteroids (VII) with thiourea in boiling methanol, a mixture of 2'-aminothiazolo-1 α -hydroxysteroids (VIII) and bis(3-ketosteroid-1-en-2-yl)sulfides (IX) were obtained (14).

Table I




R	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	References
H	α-H	H	H	H ₂	H	β-OH α-H	H	1,5
Δ ⁴	-	H	H	H ₂	H	β-OH α-H	H	1
α-CH ₃	α-H	H	H	H ₂	H	β-OH α-H	H	1
H	α-H	H	H	H ₂	H	β-OH	H	1
H	α-H	α-CH ₃	H	H ₂	H	α-C ₂ H ₅ β-OH α-H	H	1
Δ ⁴	-	Δ ⁶ , CH ₃	H	H ₂	H	β-OH α-CH ₃	H	1
Δ ⁴ , Cl	-	H	α-F	O	H	β-OH α-CH ₃	H	1
Δ ⁴ , Br	-	H	α-F	O	H	β-OH α-CH ₃	H	1
Δ ⁴	-	α-F	H	β-OH α-H	H	β-OH α-H	H	1
H	α-H	H	H	H ₂	H	β-OH α-H	CH ₃	1,5
Δ ⁴	-	H	H	H ₂	H	β-OH α-H	CH ₃	1
α-CH ₃	α-H	H	H	H ₂	H	β-OH α-H	CH ₃	1
H	α-H	H	H	H ₂	H	β-OH α-C ₂ H ₅	CH ₃	1,6
H	α-H	α-CH ₃	H	H ₂	H	β-OH α-H	CH ₃	1
Δ ⁴	-	Δ ⁶ , CH ₃	H	H ₂	H	β-OH α-CH ₃	CH ₃	1
Δ ⁴ , Cl	-	H	α-F	O	H	β-OH α-CH ₃	CH ₃	1
Δ ⁴ , Br	-	H	α-F	O	H	β-OH α-CH ₃	CH ₃	1
Δ ⁴	-	α-F	H	β-OH α-H	H	β-OH α-H	CH ₃	1
H	α-H	H	H	H ₂	H	β-OH α-H	OC ₂ H ₅	1
Δ ⁴	-	H	H	H ₂	H	β-OH α-H	OC ₂ H ₅	1
α-CH ₃	α-H	H	H	H ₂	H	β-OH α-H	OC ₂ H ₅	1
H	α-H	H	H	H ₂	H	β-OH α-C ₂ H ₅	OC ₂ H ₅	1
H	α-H	α-CH ₃	H	H ₂	H	β-OH α-H	OC ₂ H ₅	1
Δ ⁴	-	Δ ⁶ , CH ₃	H	H ₂	H	β-OH α-CH ₃	OC ₂ H ₅	1
Δ ⁴ , Cl	-	H	α-F	O	H	β-OH α-CH ₃	OC ₂ H ₅	1
Δ ⁴ , Br	-	H	α-F	O	H	β-OH α-CH ₃	OC ₂ H ₅	1
Δ ⁴	-	α-F	H	β-OH α-H	H	β-OH α-H	OC ₂ H ₅	1
H	α-H	H	H	H ₂	H	β-OH α-H	C ₆ H ₅	1

Table I, continued

Δ^4	-	H	H	H ₂	H	β -OH α -H	C ₆ H ₅	1
α -CH ₃	α -H	H	H	H ₂	H	β -OH α -H	C ₆ H ₅	1
H	α -H	H	H	H ₂	H	β -OH α -C ₂ H ₅	C ₆ H ₅	1
H	α -H	α -CH ₃	H	H ₂	H	β -OH α -H	C ₆ H ₅	1
Δ^4	-	Δ^6 , CH ₃	H	H ₂	H	β -OH α -CH ₃	C ₆ H ₅	1
Δ^4 , Cl	-	H	α -F	O	H	β -OH α -CH ₃	C ₆ H ₅	1
Δ^4 , Br	-	H	α -F	O	H	β -OH α -CH ₃	C ₆ H ₅	1
Δ^4	-	α -F	H	β -OH α -H	H	β -OH α -H	C ₆ H ₅	1
H	α -H	H	H	H ₂	H	β -OH	H	2,3,4,5
H	α -H	H	H	H ₂	H	α -CH ₃ β -OH	CH ₃	2,3,4,5,6
H	α -H	H	H	H ₂	H	α -CH ₃ β -OH	NH ₂	2,3
H	α -H	H	H	H ₂	H	β -OH α -CH ₃	NHCH ₂ CH=CH ₂	2,3
H	α -H	H	H	H ₂	H	β -OH α -CH ₃	NHC ₆ H ₅	2,3
H	α -H	H	H	H ₂	H	β -C ₈ H ₁₇ α -H	H	3
H	α -H	H	H	H ₂	H	β -C ₈ H ₁₇ α -H	CH ₃	3
H	α -H	H	H	H ₂	H	β -C ₈ H ₁₇ α -H	NH ₂	3,7
H	α -H	H	H	H ₂	H	β -C ₈ H ₁₇ α -H	NHCH ₂ CH=CH ₂	3
H	α -H	H	H	H ₂	H	β -C ₈ H ₁₇ α -H	NHC ₆ H ₅	3
H	α -H	H	H	H ₂	H	β -OH α -H	NH ₂	8
H	α -H	H	H	H ₂	H	β -OCOCH ₃ α -H	NH ₂	8
H	α -H	H	H	H ₂	H	β -OCO(CH ₂) ₂ CH ₃ α -H	NH ₂	8
H	α -H	H	H	H ₂	H	β -OCO(CH ₂) ₂ COOH α -H	NH ₂	8
H	α -H	H	H	H ₂	H	β -OCOC ₆ H ₅ α -H	NH ₂	8
H	α -H	H	H	H ₂	H	β -OCOCH=CHC ₆ H ₅ α -H	NH ₂	8
Δ^4	-	H	H	H ₂	H	β -OH α -H	NH ₂	9
Δ^4	-	H	H	O	H	=CHCOOCH ₃	NH ₂	10
Δ^4	-	H	H	O	CH ₃	Bismethylenedioxy	SH	11
Δ^4	-	H	H	O	CH ₃	Bismethylenedioxy	H	11
Δ^4	-	H	H	β -OH α -H	CH ₃	Bismethylenedioxy	H	11
Δ^4	-	H	H	β -OH α -H	CH ₃	β -COCH ₂ OH α -OH	H	11


Esterification of compounds belonging to reference 1 produced the acetate, propionate, butyrate, cyclopropionate and benzoate derivatives.

Table II



R	R ₁	R ₄	R ₅	R ₆	R ₇	[α] _D	References
H	α-H	H ₂	H	β-OH α-CH ₃	H	+48.8° +33° +33°, +37°, +37°	2,3 4 5
H	α-H	H ₂	H	β-OH α-CH ₃	CH ₃	+35.6° +47° +47°, +42°, +44°	2,3 4 5
H	α-H	H ₂	H	β-OH α-CH ₃	NH ₂	+45°	2,3
H	α-H	H ₂	H	β-OH α-CH ₃	NHCH ₂ CH=CH ₂	+50.5°	2,3
H	α-H	H ₂	H	β-OH α-CH ₃	NHC ₆ H ₆	+46°	2,3
H	α-H	H ₂	H	β-C ₆ H ₁₇ α-H	CH ₃	+52.9° (c = 0.81, chloroform)	3
H	α-H	H ₂	H	β-C ₆ H ₁₇ α-H	NH ₂	+64.4° (c = 0.496) +58.3° (c = 0.78, chloroform)	7 3
H	α-H	H ₂	H	β-C ₆ H ₁₇ α-H	NHCH ₂ CH=CH ₂	+57.4° (c = 1.03, chloroform)	3
H	α-H	H ₂	H	-β-C ₆ H ₁₇ β-OH α-H	NHC ₆ H ₅ NH ₂	+62.9° (c = 0.99, chloroform) +67.8° ± 0.2° (1% 95% ethanol)	3 8
H	α-H	H ₂	H	β-OH α-H	H	+91°	5
H	α-H	H ₂	H	β-OH α-H	CH ₃	+64°	5
H	α-H	H ₂	H	β-OH α-C ₂ H ₅	CH ₃	+36°	6
Δ ⁴	-	H ₂	H	β-OH	NH ₂	-100 (dioxan)	9
H	α-H	O	H	=CHCOOCH ₃	NH ₂	+150 (chloroform)	10
H	α-H	O	CH ₃	BMD	SH	+72° (c = 0.6, chloroform)	11
H	α-H	O	CH ₃	BMD	H	+121° (c = 0.5, chloroform)	11
H	α-H	β-OH	CH ₃	BMD	H	+60° (c = 0.62, chloroform)	11
H	α-H	β-OH	CH ₃	β-COCH ₂ OH	H	+150° (c = 0.43, chloroform)	11

BMD = Bismethylenedioxy



- a, R = COCH₃, R₁ = H
 b, R = OCOCH₃, R₁ = H
 c, R = β-CH₃
 α-OCOCH₃, R₁ = H
 d, R = COCH₃, R₁ = OCOCH₃

Steroido[2,3-*d*]thiazoles.

Steroido[2,3-*d*]thiazoles were also obtained on the basis of the corresponding α-haloketones. In the condensation

of 3α-bromo-2-ketosteroids (X) with thioformamide, thioacetamide or thiobenzamide, in alcoholic solution [2,3-*d*]thiazoles (XI) are obtained which contain hydrogen, methyl or phenyl substituents in position 2' of the thiazole ring (15).

The compounds prepared are listed in Table IV.





Table III







R	R ₁	R ₄	R ₅	R ₆	R ₇	λ max (ethanol)	mμ (loge)	ε	λ max (chloroform)	References
H	α-H	H ₂	H	β-OH α-CH ₃	H	251 252 252	(3.64) (3.61) (3.61)		2.75, 3.00-3.05, 6.40 3.01, 6.47 (very short) (1)	2,3 4 5
H	α-H	H ₂	H	β-OH α-CH ₃	CH ₃	253 254 254	(3.72) (3.76) (3.76)		2.76, 6.40 3.07 (ms), 6.39 (w) (1)	2,3 4 5
H	α-H	H ₂	H	β-OH α-CH ₃	NH ₂				2.76, 2.86, 2.94, 6.25, 6.57	2,3
H	α-H	H ₂	H	β-OH α-CH ₃	NHCH ₂ CH=CH ₂	266	(3.93)		2.76, 2.90, 6.07 6.27, 6.49	2,3 2,3
H	α-H	H ₂	H	β-OH α-CH ₃	NHC ₆ H ₅	298	(4.21)		2.76, 2.90, 3.06, 6.19, 6.48 6.64 (1)	2,3 3
H	α-H	H ₂	H	β-C ₈ H ₁₇	CH ₃				6.12, 6.41 (1)	3
H	α-H	H ₂	H	β-C ₈ H ₁₇	NH ₂				2.82-3.02, 6.13-6.25, 6.1, 6.53 (1)	3
H	α-H	H ₂	H	β-C ₈ H ₁₇ α-H	NHCH ₂ CH=CH ₂				2.92, 6.07, 6.30, 6.49	3
H	α-H	H ₂	H	β-C ₈ H ₁₇ α-H	NHC ₆ H ₅				2.93, 6.21, 6.50, 6.67	3
H	α-H	H ₂	H	β-OH α-H	H	252	(3.69)			5
H	α-H	H ₂	H	β-OH α-H	CH ₃	254	(3.74)		3.06 (ms), 6.40 (ms) (1)	5
H	α-H	H ₂	H	β-OH α-C ₂ H ₅	CH ₃	254-256	(3.71)			6
H	α-H	H ₂	H	β-OH α-H	NH ₂	263		7000		8
Δ ⁴		H ₂	H	β-OH α-H	NH ₂	264.5		7470		9
H	α-H	O	CH ₃	BMD	SH	248, 327, 333, 246, 293		11200, 13200, 13600 (3), 20000, 10600 (4)	3-3.2, 3.7, 5.88, 6.23,	11
H	α-H	O	CH ₃	BMD	H	271 (2)		8400	5.88, 6.1, 6.5, 9.06	11
H	α-H	β-OH α-H	CH ₃	BMD	H	263		9680 (3)	2.75, 3, 6.1, 6.5, 9.08	11
H	α-H	β-OH α-H	CH ₃	β-COCH ₂ OH α-OH	H	263		8500 (3)	3-3.1, 5.8, 6.15, 6.52	11
H	α-H	H ₂	H	β-C ₈ H ₁₇ α-H	NHCOH	285	(3.94) (2)			12
H	α-H	H ₂	H	β-OCOCH ₃	NHCOH	280	(4.10)			12

(1) Potassium bromide. (2) Chloroform. (3) Methanol. (4) Methanol-sodium hydroxide.


BMD = Bismethylenedioxy.

Table IV


R	R ₁	R ₂	Reference
H	H	H	15
COCH ₃	H	H	15
COC ₆ H ₅	H	H	15
H	β-CH ₃	H	15
COCH ₂ CH ₃	β-CH ₃	H	15
 CH ₂ CH ₂ OC	β-CH ₃	H	15
H	α-CH=CH ₂	H	15
COCH ₃	α-CH=CH ₂	H	15
CO(CH ₂) ₄ CH ₃	α-CH=CH ₂	H	15
H	α-C ₂ H ₅	H	15
COCH ₂ CH ₃	α-C ₂ H ₅	H	15
 CH ₂ CH ₂ OC	α-C ₂ H ₅	H	15
H	H	CH ₃	15
COCH ₃	H	CH ₃	15
COC ₆ H ₅	H	CH ₃	15
H	α-CH ₃	CH ₃	15
COCH ₂ CH ₃	α-CH ₃	CH ₃	15
 CH ₂ CH ₂ OC	α-CH ₃	CH ₃	15
H	α-CH=CH ₂	CH ₃	15
H	α-C ₂ H ₅	CH ₃	15
H	H	C ₆ H ₅	15
COCH ₃	H	C ₆ H ₅	15
COC ₆ H ₅	H	C ₆ H ₅	15
H	α-CH ₃	C ₆ H ₅	15
COCH ₂ CH ₃	α-CH ₃	C ₆ H ₅	15
 CHCH ₂ OC	α-CH ₃	C ₆ H ₅	15
H	α-CH=CH ₂	C ₆ H ₅	15
H	α-C ₂ H ₅	C ₆ H ₅	15

Steroido[5,6-*d*]thiazoles.

Thiazole derivatives condensed with the steroidal frame skeleton in positions 5 and 6 were obtained by reaction of 6α-bromo-3,5-seco-4-norcholestan-5-on-3-oic acid (XII) with thioacetamide or thiosemicarbazide in ethanol (16).

Steroido[11,12-*d*]thiazoles.














The reaction of 12α-thiocyanato-11-ketosteroids (XIV) with secondary amines in boiling dioxane leads to the [11,12-*d*]thiazole derivatives (XV) (17).



Refluxing 2'-diethylaminothiazolo[11,12-*d*]5α-pregn-11-ene-3β,20β-diacetate with potassium carbonate in aqueous methanol gave the corresponding dihydroxy compound (XVb).


Steroido[12,11-*d*]thiazoles.

In an analogous manner to the synthesis of steroido[11,12-*d*]thiazoles the reaction of 11β-thiocyanato-12-ketosteroids (XVI) with secondary amines produced the [12,11-*d*]thiazoles (XVII) (18-19).



Steroido[17,16-*d*]thiazoles.

The usual method for the synthesis of the title compounds involves the reaction of 16 α -bromo-17-ketosteroids (XVIII) with thioacetamide or thiourea in boiling alcohol (12,20-23). When the reaction of XVIII with thiourea takes place in dimethylformamide, the 2'-formamido-thiazolosteroids are formed (12).



The compounds prepared are listed in Table V.

Saponification of 3 β -acetoxythiazolosteroids (XX) followed by Oppenauer oxidation afforded thiazolo-4-en-3-one derivatives (XXIII) (20-23), which were also obtained by reaction of 16 α -bromo-3,17-dione (XXII) (22) with thioacetamide or thiourea.







Table V




Compound	R	R ₁	R ₂	References
XIXa	β -OCOCH ₃	α -H	NHCOH	12
XIXb	β -OCOCH ₃	β -H	NHCOH	12
XIXc	α -OCOCH ₃	α -H	NHCOH	12
XIXd	H	α -H	NHCOH	12
XIXe	β -OCOCH ₃	Δ^5	NHCOH	12
XIXf	H	α -H	NH ₂	12
XIXg	β -OH	α -H	NH ₂	12
XIXh	β -OCOCH ₃	Δ^5	NH ₂	12
XIXi	β -OH	Δ^5	NH ₂	20,21,22
XIXk	β -OCOCH ₃	Δ^5	NHCOCH ₃	20,21,22
XIXl	β -OH	Δ^5	CH ₃	20,21,22,23
XIXm	β -OCOCH ₃	Δ^5	CH ₃	20,21,22,23

Similarly 16 α -bromoestra-1,3,5(10)-trien-17-one (XXIV) is converted by heating with thiourea in boiling alcohol (24) or in dimethylformamide (12) to 2'-amino-(XXV) or to 2'-formamidothiazoloestra-1,3,5(10),16-tetraene (XXVI), respectively.



Alternatively XXV can be obtained by treatment of 3-methoxy-2'-amino-4'-ethoxy-4',5'-dihydrothiazolo[1-7,16-*d*]-estra-1,3,5(10)triene (XXVII) with aqueous sodium hydroxide (24).

A plausible pathway for the conversion of XXVIII to XIX is a concerted process involving ring opening of the epoxide by thiourea at C-16 with the expulsion of bromide and the formation of an acyclic intermediate (12).

Steroido[20,21-*d*]thiazoles.

The standard method for the preparation of the 2'-amino- or 2'-N-substituted aminosteroido[20,21-*d*]thiazoles (XXX) involves the condensation of thiourea or its N-substituted derivatives with 21-substituted-20-ketosteroids (XXIX) in several solvents, such as acetone, ethanol or anhydrous dimethylformamide (12,25-30).






Table VI




R	R ₁	R ₂	R ₃	mp (bp °C)	Yield (%)	[α] _D (chloroform)	λ max (ethanol) mμ	(log ε)	References
H ₂	OH	H	H	226	94.4	+ 61.69 (c = 0.2378)	242.5 ~ 245	(4.24)	27
H ₂	OH	H	CH ₃	227	97.5	+ 105.4 (c = 0.8126)	243.2 ~ 244.3	(4.30)	27
H ₂	OH	H	C ₂ H ₅	211	88.7	+ 102 (c = 0.9831)	242.5 ~ 244.5	(4.09)	27
H ₂	OH	H	C ₃ H ₇	184	92.8	+ 105.2 (c = 1.077)	242.3 ~ 245	(4.07)	27
H ₂	OH	H	<i>iso</i> -C ₃ H ₇	187.5	92.8	+ 109.9 (c = 1.0159)	242.3 ~ 245	(4.29)	27
H ₂	OH	H	C ₄ H ₉	153.5	96.5	+ 96.4 (c = 1.0195)	241.5 ~ 243.5	(4.32)	27
H ₂	OH	H	<i>sec</i> -C ₄ H ₉	139	89.6	+ 100.5 (c = 0.932)	243.2 ~ 244.2	(4.29)	27
H ₂	OH	H	C ₆ H ₅	247	96.4	+ 98 (c = 0.400)	239.8 ~ 242 289 ~ 292	(4.21) (4.20)	27
H ₂	OH	H	4-CH ₃ OC ₆ H ₄	195	92.5	+ 103.4 (c = 0.847)	241.5 ~ 242.5 296	(4.28) (4.25)	27
H ₂	O	H	4-C ₂ H ₅ OC ₆ H ₄	185	92.5	+ 100.2 (c = 0.600)	241 ~ 242.5 296 ~ 298	(4.24) (4.22)	27
H ₂	OH	H	4-CH ₃ C ₆ H ₄	217	89.7	+ 102.4 (c = 0.629)	240 ~ 242 293 ~ 296	(4.16) (4.25)	27
H ₂	OH	H	2-CH ₃ C ₆ H ₄	213.5	83.3	+ 102.4 (c = 0.688)	240 ~ 242.5 293 ~ 296	(4.10) (3.87)	27
H ₂	OH	H	4-ClC ₆ H ₄	202	85.5	+ 81.1 (c = 0.073) (a)	239.8 ~ 241.8 297 ~ 300	(4.16) (4.29)	27
H ₂	OH	H	2-ClC ₆ H ₄	210	98.1	+ 58.1 (c = 0.206) (a)	238.5 ~ 241.5 293 ~ 295.5	(4.16) (4.07)	27
H ₂	OH	H	3-ClC ₆ H ₄	204	92	+ 131.1 (c = 0.240) (a)	240.5 ~ 242.5 296 ~ 298	(3.85) (3.89)	27
H ₂	OH	H	2,3-Cl ₂ C ₆ H ₃	243	86.2	+ 81.8 (c = 0.397) (a)	236 ~ 237 296 ~ 299	(3.97) (3.89)	27
H ₂	OH	H	2,5-Cl ₂ C ₆ H ₃	223	95.6	+ 102.6 (c = 0.336) (a)	236.5 ~ 238.5 293.5 ~ 295.5	(4.05) (3.95)	27
H ₂	OH	CH ₃	C ₆ H ₅	185	96.1	+ 109 (c = 0.785)	240.5 ~ 242.5 295	(4.40) (3.99)	27
H ₁	OH	C ₂ H ₅	C ₆ H ₅	151	96.2	+ 114.5 (c = 1.612)	239.3 ~ 241.8 295 ~ 296	(4.41) (4.41)	27
H ₂	OH	H		219	83.5	+ 79 (c = 0.3275)	242 ~ 244	(4.25)	27
O	OH	H	H	250	91	+ 163.1 (c = 0.309)	240.5 ~ 242	(4.35)	27
O	OH	H	CH ₃	243	90	+ 171.6 (c = 0.802)	239	(4.26)	27
O	OH	H	C ₆ H ₅	247	89	+ 11.7 (c = 0.323)	264	(3.77)	27
O	OH	CH ₃	C ₆ H ₅	214	86.5	+ 141 (c = 1.031)	241.5 295 ~ 296	(4.37) (3.79)	27
H ₂	H	H	CH ₃	219	83.9	+ 132.7 (c = 0.662)	242.5	(4.24)	27
H ₂	H	H	C ₆ H ₅	226	81.8	+ 111.4 (c = 0.984)	241 ~ 243 295 ~ 298	(4.16) (3.65)	27
H ₂	H	C ₂ H ₅	C ₆ H ₅	144	93.1	+ 123.5 (c = 0.945)	241 ~ 242 296 ~ 299	(4.51) (3.39)	27


(a) *N,N*-Dimethylformamide.

The compounds prepared and their melting points, yields, specific rotary powers and ultraviolet spectra are listed in Table VI.


Similarly 3β, 14-dihydroxy-17β-(2'-amino-4'-thiazolyl)-5β,14β-androstane-3-acetate hydrochloride (XXXII) was prepared (30).



It has been reported that the reaction of 21-bromo-3 β -hydroxy-5-pregnen-20-one (XXXIII) with thiourea in refluxing dimethylformamide yielded the 2'-formamidothiazolo[20,21-*d*]pregna-5,20-dien-3 β -ol (XXXIV) (12).




Reduction of 17 α -hydroxy-17 β -(2'-alkylamino- or 2'-aryl-amino- or 2'-*N,N*-alkylamino)-4'-thiazolyl)androst-4-ene-3-one (XXXV) with sodium borohydride in dioxane or dioxane-methanol (1:1) and subsequent purification by chromatography through acid-washed alumina yielded a sole product which corresponds to 3 β ,17 α -diol (XXXVI). (31-32).




The compounds prepared and their melting points, yields, specific rotary powers and ultraviolet spectra are listed in Table VII.

Compounds XXXV and XXXVI after the action of succinic anhydride in pyridine yielded *N*- and 3 β -*O*-succinate (XXXVII), while the aliphatic amino derivatives of XXXVI produce 3 β -*O,N*-disuccinate (31,33).



The compounds prepared and their melting points, yields, specific rotary powers and ultraviolet spectra are listed in Table VIII.

Table VII






R ₁	R ₂	mp °C	Yield	[α] _D (chloroform)	λ max (ethanol) (m μ) (log ϵ)	References
H	H	240.5	85	+16.69 (c = 0.1716)	259 ~ 260 (3.50)	31
H	CH ₃	216	90.9	+10.81 (c = 0.248)	261 ~ 264 (3.57)	31
H	C ₂ H ₅	222.5	95	+47.61 (c = 0.294)	264 ~ 266 (3.82)	31
H	C ₃ H ₇	202	70	+76.87 (c = 0.576)	265.3 ~ 266.2 (3.92)	31
H	<i>iso</i> -C ₃ H ₇	218	85	+62.76 (c = 0.415)	266 ~ 267 (3.75)	31
H	C ₄ H ₉	161	70	+37.20 (c = 0.532)	262 ~ 265 (3.81)	31
H	C ₆ H ₅	199	88.8	+43.74 (c = 0.901)	295.5 (4.23)	31
H		212	80	39.09 (c = 0.024)	264.5 ~ 265.7 (3.76)	31
H	2-CH ₂ C ₆ H ₄	192	60	+43.03 (c = 1.162)	293 ~ 294 (4.00)	31
H	4-CH ₂ C ₆ H ₄	202	82.3	+18.94 (c = 1.162)	295.5 ~ 296.5 (4.06)	31
H	3-ClC ₆ H ₄	209	79	+79.36 (c = 0.794)	298 ~ 299 (4.27)	31
					254 (3.81)	
C ₂ H ₅	C ₆ H ₅	214	73.3	+58.73 (c = 0.794)	260.5 (3.72)	31
					295 ~ 298 (3.82)	

Table VIII




R	R ₁	R ₂	mp °C	Yield	[α] _D (chloroform)	λ max (ethanol) (mμ)	(log ε)	References
O	COCH ₂ CH ₂ COOH	H	217	70.5	-57.73 (c = 0.433)	242 ~ 243	(4.14)	31
α-H	COCH ₂ CH ₂ COOH	H				227.5 ~ 228	(4.37)	31
β-OCOCH ₂ CH ₂ COOH	COCH ₂ CH ₂ COOH	CH ₃	142	61.2	+133.33 (c = 0.075)	235.2 ~ 235.8	(4.37)	
						243.5 ~ 244	(4.21)	
						275 ~ 276.5	(3.98)	
α-H	β-OCOCH ₂ CH ₂ COOH	H						
β-OCOCH ₂ CH ₂ COOH	H	4-CH ₃ C ₆ H ₄	176	65.2	+49.32 (c = 1.774)	293.5 ~ 294.5	(3.24)	31
α-H	β-OCOCH ₂ CH ₂ COOH	H						
β-OCOCH ₂ CH ₂ COOH	H	2-CH ₃ C ₆ H ₄	182	70	+70.54 (c = 0.283)	290.5 ~ 292	(4.06)	31

The reaction of XXIX with ammonia and carbon disulphide in ethanol leads to a 2'-mercaptoderivative (XXVIII) (25).




- a, R = H₂, R₁ = H
b, R = O, R₁ = OH



- a, R = R₁ = R₂ = H
b, R = OH, R₁ = R₂ = H
c, R = OCOCH₃, R₁ = R₂ = H
d, R = R₁ = OCOCH₃, R₁ = R₂ = H
e, R = R₁ = R₂ = OCOCH₃


Similarly 2'-hydroxy derivatives (XL) were prepared by treatment of 21-thiocyanato-20-ketosteroids (XXXIX) with concentrated hydrochloric acid in boiling 2-propanol (25).



- a, R = O, Δ⁴
b, R = α-H, β-OH, Δ⁵

Benzylation and acetylation of XLIIa and XLIIc afforded the corresponding *N*-Benzyl (XLIIId) and *N*-acetoxy-derivatives (XLIIe) (34).

Furthermore, treatment of XLIIa and XLIIc with concentrated hydrochloric or hydrobromic acid and BuONO respectively, produced the 2-Cl (XLIIIf) and 2-Br compounds (XLIIIf) (34).



- a, R = R₁ = R₂ = OH, R₃ = NHCH₂C₆H₅
b, R = R₁ = OCOCH₃, R₂ = H, R₃ = NHCOCH₃
c, R = R₁ = R₂ = OH, R₃ = Cl
d, R = R₁ = R₂ = OCOCH₃, R₃ = Br

Steroido[23,22-*d*]thiazoles.


The treatment of the 22-bromo-23-ketocholanic acid piperidylamides (XLI) with thiourea in boiling alcohol yielded 2'-amino-5'-(20-ternocholanyl)-4'-thiazole-carboxylic acid piperidylamides (XLIIa-e) (34).

Steroido[24,23-*d*]thiazoles.


As starting substance for the preparation of the above thiazoles the 24-phenyl-23-bromo-3α,6α-diacetoxy-5β-

cholane-24-one (XLIV) was chosen, which condensed with thiourea in boiling ethanol (35).

Tosylation of XLVc and heating with potassium acetate in aqueous dimethylformamide of the XLVd, yielded a mixture of two products XLVIa and XLVIb. Acetylation of the reaction mixture led to the 3β -acetoxy- Δ^4 -steroid (XLVIb) which was converted into the 3β -hydroxy- Δ^4 -steroid (XLVIa) (35).




- a, $R_1 = R_2 = \text{COCH}_3$
 b, $R_1 = \text{COCH}_3, R_2 = \text{H}$
 c, $R_1 = \text{H}, R_2 = \text{COCH}_3$
 d, $R_1 = \text{Ts}, R_2 = \text{COCH}_3$



- a, $R_1 = \text{H}$
 b, $R_1 = \text{COCH}_3$


Steroidal thiazoles in which the heterocyclic ring is not condensed with the steran skeleton have been reported by Yoneno (36). Starting with 3,3-ethylenedioxy-17-oxo-5-androstene (XLVII) by treatment with lithium and 2-bromothiazole obtained the 3,3-ethylenedioxy-17 α -(2-thiazolyl)-17 β -hydroxy-5-androstene (XLVIII) which with acetic acid produced the final product, 3-oxo-17 α -(2-thiazolyl)-17 β -hydroxy-4-androstene (XLIX).




Mass Spectra of Aminothiazolosteroids (12).

The base peak (100%) of compound IVb occurred at

m/e 126 corresponding to the ion $\text{H}_2\text{N}-\text{S}-\text{N}$: A metastable peak at m/e 35.92 shows that this peak (m/e 126) arises directly from M^+ , path β . The molecular ion m/e 442, has a medium intensity. Further fragmentation of compound IVb is shown in Scheme 1.




Scheme 1




$\text{C}_{28}\text{H}_{46}\text{N}_2\text{S}$ (MW 442)

The spectrum of XIXg ($\text{R} = \beta\text{-OH}, R_1 = \alpha\text{-H}, R_2 = \text{NH}_2$) reveals a peak (100%) at m/e 331, which originates by the loss of $\cdot\text{CH}_3$ from M^+ , as it is shown from m^* at m/e 316.65. The molecular ion at m/e 346 is rather abundant (50% based on the base peak). The most interesting fragmentation peaks are shown in Scheme 2.




Scheme 2








The possible pathways for the formation of the base peak (100%) at m/e 311 of the compound XIX (R = β -OCOCH₃, R₁ = Δ^5 , R₂ = NH₂) are shown below.






Further, the ion ($M^+ - 60$) 326 possibly arises from M^+ by the loss of $S=C=NH_2$, m/e 60, path β (Scheme 3). Further fragmentation peaks are shown in Scheme 3.




The peaks of the fragmentation of the formamidothiazolosteroids XIXb (R = β -OCOCH₃, R₁ = β -H, F₂ = NHCOH), XIXc (R = α -OCOCH₃, R₁ = α -H, R₂ = NHCOH), XIXd (R = H, R₁ = α -H, R₂ = NHCOH) and XXXIV are presented in Schemes 4-7.




Scheme 4





Scheme 5

M⁺(416)



The fragmentation of this compound is similar to that of XIX (R = β -OCOCH₃, R₁ = α -H, R₂ = NHCOH), except for the observed peak intensities. The base peak (100%) is at m/e 401 ($M^+ - CH_3$).



Scheme 6




Scheme 7




Steroidal Thiazolines.


Steroido[3,2-*d*]thiazolines.

Condensation of 2 α -thiocyanatoandrostan-3-one (L) with *o*-toluidinehydrochloride in boiling ethanol produced a 2-androsten[3,2-*d*]thiazoline (37). By this method various *N*-substituted derivatives (LI) were obtained.





- a, R = NH, R₁ = C₆H₅
 b, R = NH, R₁ = o-CH₃C₆H₄
 c, R = NH, R₁ = p-CH₃C₆H₄
 d, R = NH, R₁ = o-CH₃OC₆H₄
 e, R = NH, R₁ = p-CH₃OC₆H₄
 f, R = NH, R₁ = p-ClC₆H₄
 g, R = N , R₁ = H



When the 2 α -thiocyanatocholestan-3-one (LII) was heated in dioxane containing aqueous hydrochloric acid, cyclization took place to give oxothiazoline (LIII) (38).



Campbell and Craig (39) reported the synthesis of 2'-thioxo-2 β ,2', 3 β ,3'-tetrahydro-5 α -androst-2-eno[3,2-*d*]-thiazol-17-one. Starting from 3 α -amino-2 β -chloro-5 α -androstan-17-one (LIV), which on treatment with carbon disulfide followed by methylation afforded LVI.




The same authors (39) describe an alternate route to the synthesis of thiazolines from the α -aziridine which involved *N*-thioacylation with phenylisothiocyanate.




α -Aziridine (LVII) with phenylisothiocyanate produced an unstable thiocarbamoyl aziridine (LVIII). Ring expansion of LVIII by sodium iodide in acetone produced by trans-diazial ring opening, the 2 β -iodo-compound (LIX) which cyclized to the thiazolidine (LX) or its tautomer (LXI).

The *vic*-iodoisothiocyanates inseparable mixture (1:7) (LXII) and (LXIII) derived from 5 α -androst-2-ene reacts with aniline in the dark, forming compounds LXIV and LXV in a ratio 1:6, which are separated by p/c (40).




2 α -Bromo-cholestan-3-one (LXVI) in condensation with ammonium dithiocarbamate formed cholestanthioxothiazolidine (LXVII), the dehydration of which yielded the corresponding cholestanthioxothiazoline (LXVIII) (41).




Steroido[2,3-*d*]thiazolines.

The reaction of 2 β ,3 β -dihydro-5 α -androst-2-eno[2,3-*\beta*]-azirin-17-one ethylene acetal (LXIX) with phenylisothiocyanate produced an unstable thiocarbamoyl aziridine (LXX), which was transformed by sodium iodide *via* the 3 α -iodointermediate (LXXI) into the 2 β ,3 β -thiazolidine (LXXII) or its tautomer (LXXIII) (39).




Treatment of the 4-chloro- Δ^4 -3-ketosteroids (LXXIV) with thiourea produced compounds LXXV or LXXVI. It is

not known whether the compounds possess [2,3-*d*] or [4,5-*d*] structure (9).




Steroido[3,4-*d*]thiazolines.

Thiazolines derivatives condensed with the steroidal skeleton in position C-3, C-4 are formed by treatment of 4 ζ ,5 ζ -epoxyandrostanes (LXXVII) with thiourea or *N,N*-substituted thiourea (42). Quaternary salts were obtained by the action of methyl iodide on LXXVIII or LXXIX.




Column chromatography for separation of the mixture 4 α -thiocyanato- (LXXXI) and 4 β -thiocyanatocholestan-3-one (LXXXII) by alumina led to the isolation of the 2'-oxo[3,4-*d*]thiazoline (LXXXIII) (38).




Steroido[5,6-*d*]thiazolines.

Passing of dry hydrogen chloride gas in a cooled suspension of 5 α -hydroxy-6 β -thiocyanato-5 α -pregnane-3,20-dione (LXXXIV) in acetic acid produced, 2'-chloro-thiazolino[5,6-*d*]5 α -pregnane-3,20-dione (LXXXV) (43-44).




Steroido[11,9-*d*]thiazolines.

The 9 α -thiocyanato-11-keto-steroids (LXXXVI) were suitable starting material for the preparation of 2'-ethoxy- or 2'-methoxythiazolino[11 α ,9 α -*d*]steroids (LXXXVII). Treatment of LXXXVI with aqueous methanolic or ethanolic potassium carbonate produced LXXXVII (45-46).




The compounds prepared are presented in Table IX.

Table IX



No.	R	R ₁	R ₂	R ₃
a.	O	Δ^4	O	CH ₃
b.	O	Δ^4	$\beta\text{-COCH}_2\text{OH}$	CH ₃
c.	O	Δ^4	$\beta\text{COCH}_2\text{OOCCH}_3$	CH ₃
d.	O	Δ^4	O	C ₂ H ₅
e.	O	Δ^4	$\beta\text{-OH}$	CH ₃
f.	O	Δ^4	O	CH ₃ Δ^1
g.	$\beta\text{-OH}$	Δ^4	$\beta\text{-OH}$	CH ₃
h.	O	$\alpha\text{-H}$	O	CH ₃


The 2'-methoxythiazolino[11 α ,9 α -*d*]steroids (LXXXVIIa-c) were isomerized to 2'-methoxy-5',6'-dihydro-4'*H*-1',3'-thiazino[4',5',6':5 α ,10,9 α]steroids (LXXXVIII) upon refluxing in a methanolic solution or fusing at 178-182°.



- a, R = R₂ = O, R₃ = CH₃
 b, R = O, R₂ = $\beta\text{COCH}_2\text{OH}$, R₃ = CH₃
 c, R = O, R₂ = $\beta\text{COCH}_2\text{OOCCH}_3$, R₃ = CH₃

This rearrangement involves the rupture of the C-N bond at C-11 of the thiazole ring and the reattachment of the nitrogen bearing function to C-5 with the resultant for-


In contrast, the reaction of 16 α ,17 α -epiminopregnenolone-3,*N*-diacetate with thioacetic acid yields a complex mixture of products, since the reaction of 16 α ,17 α -epiminopregnenolone-20-carbethoxyhydrazone (CII) with thioacetic acid gave mainly two products: 2'-methylpregn-5-en-3 β -ol-20-one[16 α ,17 α -*d*]thiazoline 20-carbethoxyhydrazone (CIII) and 16 α -acetylaminopregn-5-en-3 β -ol-20-one 20-carbethoxyhydrazone (CIV) (49).



In an aqueous methanol solution the carbethoxyhydrazones (CIII) and (CIV) yield the ketones CV and CVII respectively.


The reaction is sensitive to very small changes in conditions.

Generally an alkaline or acidic medium during treatment favors the formation of CIV. It may be assumed that formation of both reaction products proceeds through one and the same intermediate. The following mechanism may be proposed to explain the observed course of the reaction. The protonated form of the aziridine, under the influence of the hydrazone fragment undergoes *cis*-scission with the introduction of a SCOCH_3 ion at the 17 position to form a 17 α -thioacetate-16 α -amine. Allowing for the tendency of systems with *cis*-oriented substituents to undergo acyl migration an intermediate stage such as C, has been postulated, that stabilizes itself by forming the thiazoline (CIII) and the 16 α -acetylamine (CIV). In confirmation it may be said that the formation of the C type intermediate both in the acid-catalyzed acyl migration of *S*-acetylthioamides and in the acid hydrolysis of thiazolines is kinetically demonstrated.



Formation of a thiazoline in this reaction is possible only if the principle of *cis*-scission of the aziridine is observed; therefore, the location of the heteroatoms and the α -configuration of the heterocyclic ring must be assigned by analogy with the above described heterocyclizations that occur under the same conditions (48).

20-Carbethoxyhydrazone (CVIII) reacts extremely readily with thiocyanic acid producing the 2'-aminothiazoline (CIX) (50).





The mechanism for the *cis* opening of 16 α ,17 α -epimino-20-ketosteroids in the presence of a reagent for the CO group, assumes, that the formation of 16 α ,17 α -epimino-steroid 20-carbethoxyhydrazones is the step preceding the *cis* opening of the aziridine.

Steroidal Thiazolidines.


Steroido[3,2-*d*]thiazolidines.

The introduction of the thioxothiazolidine (LV and LX-VII) and phenyliminothiazolidine (LX) groupings in the 2,3-position of cholestane (41) and androstane (39) series has been presented in the thiazoline chapter.






A mixture of androstanethiazolidine-2-ones (CX) and (CXI) in a ratio 1:6.3 separated by plc were formed by heating of the *vic*-isothiocyanates (LXXII) and (LXXIII) under reflux in the dark with anhydrous methanol in tetrahydroethylene (40).




In the thiazoline chapter the synthesis of 2'-phenyl-iminoandrostan[2 β ,3 β -*d*]thiazolidine (LXXII) (39) has been presented.



The preparation of 2'-oxoandrostan[2 β ,3 β -*d*]thiazolidine (CXI) was also reported above.


Steroids[2,3-*d*]thiazolidines having a thioxy-group at 2'-position were prepared by Ponsold and Preibsch (51). Thus in the reaction of 3 α -chloro-2 β -amino-5 α -androstan-17 β -ol (CXIII) with carbon disulfide and alkali the 17 β -hydroxy-2'-thioxy-2',3',4',5'-tetrahydro-5 α -androstan-2-eno[2 β ,3 β -*d*]thiazole (CXIV) was obtained. Its isomer 17 β -hydroxy-2'-thioxy-2',3',4',5'-tetrahydro-5 α -androstan-2-eno[2 β ,3 α -*b*]thiazole (CXV) was also prepared from 2 β ,3 β -imino-5 α -androstan-17 β -ol (CXII) by the same method.

The nucleophilic action of HSCN on 2 β ,3 β -(cyanoimino)cholestan (CXVI) produced the 2'-imino-3'-cyanothiazolidino[2 β ,3 α -*d*]cholestan (CXVIII), by ring closure of the intermediate 2 β -(cyanoimino)-3 α -thiocyanatocholestan (CXVII) (52).





Steroids[5,6-*d*]thiazolidines.

The 2'-chloro[5 α ,6 α -*d*]thiazolidine (LXXXV) on treatment with zinc dust in acetic acid was transformed into 2'-oxothiazolidine (CXIX) (43).



Steroids[16,17-*d*]thiazolidines.



The synthesis of 20-ketosteroid[16 α ,17 α -*d*]fused to 1,3-thiazolidine was described by Kamernitskii and his co-workers (53). Thus the treatment of 20-carbethoxyhydrazone (CXXI) with hydrogen sulfide in acetone-dioxan afforded 2',2'-dimethyl-(3 β -hydroxy-20-ethoxycarbonylhydrazono-5-pregnenolone[16 α ,17 α -*d*]-1',3'-thiazolidine (CXXII), which is cleaved to the free carbonyl compound (CXXIII) with dilute hydrochloric acid in methanol-acetone.



When an alcoholic solution of 3-ketosteroids was added to an aqueous alcoholic solution of L(+)-cysteine hydrochloride or L(+)-cysteine ethyl ester hydrochloride buffered with potassium acetate, spiro[steroid-3,2'-thiazolidines-4'-carboxylic acid] (CXXIX) and spiro[steroid-3,2'-thiazolidines-4'-carboxylic acid ethyl ester] (CXXX) were formed (56-57).

Steroido[17,16-*d*]thiazolidines.

2'-Thioxo-estrathiazolidines (XCV) have been presented in the thiazoline chapter.



Spirothiazolidines.

Saturated 3-ketosteroids (CXXIV) reacted with β -mercaptoethylamine in ethanol, pyridine (54) or in benzene in the presence of *p*-toluenesulphonic acid (55) at room temperature to form steroid-3,2'-spirothiazolidines (CXXV), the acetylation of which afforded the *N*-acetyl-derivatives.

The compounds prepared are listed in Table X.





Table X

R	R ₁	R ₂	R ₃	R ₄	Reference
α -H	H	H ₂	C ₈ H ₁₇	H	53,54
β -H	H	H ₂	C ₈ H ₁₇	H	53
α -H	H	H ₂	C ₈ H ₁₇	COCH ₃	53,54
Δ^4	OH	H ₂	OCOCH ₃	H	53
Δ^4	OCOCH ₃	H ₂	OCOCH ₃	H	53
Δ^5	OH	H ₂	β -COCH ₃	H	53
			α -OH		
Δ^5	H	O	COCH ₃	H	53


Cholestan-3,2'-spirothiazolidine was also prepared by introduction of hydrogen sulfide in an alcoholic solution of cholestanone and ethylenimine (54).

Condensation of 3-cholestanone (CXXVI) with cysteine followed by acetylation and diazomethane methylation led to the compound CXXVII (55).

Treatment of spiro[cholestan-3,2'-thiazolidine-4'-carboxylic acid ethyl ester] (CXXX) R = C₈H₁₇) with phenylisocyanate the *N*-phenylhydantoin (CXXXI) was isolated (57).




Spiro(steroid)thiazolidines attached to the steroidal side chain were prepared by bringing 3-oxo-pregn-4-ene-20 β -carboxaldehyde (CXXXII) to react with various amino-thiols (58).



Acetylation of CXXXIIIa produced the *N*-acetyl-derivative CXXXIIIId.

Spirothiazolidinones.


Cyclocondensation of 5 α -cholestan-3-one (CXXXV) with thioglycolic acid and ammonium carbonate (55) produced two diastereoisomers CXXXVIa and CXXXVIIa of the 4-thiazolidinone.



Alkylation or acylation of CXXXVIa produced compounds (XXXVIIb-h) whereas the epimer CXXXVIIa produced only (XXXVIIb-c) due to steric hindrance (59).

Compounds (XXXVIIe and XXXVIIi) were also prepared by cyclocondensation of CXXXV with thioglycolic acid and RNH₂ (R = C₆H₅CH₂, C₆H₅) (59).

Similarly spirothiazolidinones CXXXVIII, CXXXIX, CXL and CXLI were prepared (60).




The compounds formed, exist in two possible steric modifications since the thiazolidine ring is at a right angle to the plane of the steroid nucleus. Consequently an isomer can be considered to have the sulphur atom of the heterocyclic ring above the plane of the nucleus while the sulphur atom of the second isomer would be below the plane of the nucleus (57).

Spiro[cholestanethiazolidin]ones CXXXVIa and CXXXVIIa isomerized under acidic, basic and thermal conditions, whereas *N*-alkyl derivatives CXXXVIb-d and CXXXVIIb did not isomerize under basic conditions (61).


Modified Steroidal Aminothiazoles.

The attachment of an aminothiazole ring to the modified cyclopentanoperhydrophenanthrene system was effected by the reaction of bromoketone (CXLII) with *N*-phenylthiourea producing 2'-phenylaminothiazolo[3,4-*d*]-6-aza-B-homo-5 α -cholestan-7-one (CXLIII) (62).



This compound must be assigned an angular structure CXLIII instead of the linear structure CXLIV (62).

Cyclocondensation of the bromosolasodane (CXLV) with ZNNHC(S)NH₂ [Z = cyclopentylidene, NO₂C₆H₄CH, (C₆H₅)₂C, C₆H₅CH=CHCH, C₆H₅CH=CHCCH₃, decahydronaphthylidene, ((CCH₃)₂NCO)C₆H₄CH, HOC₆H₄CH] produced the corresponding aminothiazole derivative (CXLVI) (63).




Reaction of CXLV with thiourea afforded the 2'-aminothiazolo[3,2-*d*]solasodane (63).

Steroidal Isothiazoles.

Steroido[17,16-*d*]isothiazoles.

The Beckmann rearrangement of 3 β -acetoxy-16 β -mercapto-17 α -hydroxy-5-pregnen-17-one oxime (CXLVII) upon the action of phosphorus oxychloride gives 3 β -acetoxy-17 α -hydroxy-3'-methylisothiazolino[17,16-*d*]androst-5-ene (CXLVIII) which on dehydration leads to androsteno[17,16-*d*]isothiazole derivative (CXLIX) (20,64-65), according to the following equation.



Biological Activity of Thiazole-steroids and Their Derivatives.

The broad spectrum of the physiological activity of steroids in which a cyclopentanoperhydrophenanthrene system is condensed with thiazolium or thiazoline ring has drawn the attention of the medicinal chemists to this class of steroids.

The study from the biological aspect of the alkaloids of the steroid series which show interesting physiological activity, showed that many of them, such as cardiac glycosides interact specifically at the cardiotonic steroid binding site of Na^+ , K^+ -AT face.

Biological tests showed that the 17β -hydroxyandrostano[3,2-*d*]thiazoles (II) possessed anabolic, antigonotropic and antiestrogenic activity (1). Similar structure compounds showed anabolic, androgeno-activity (2,4-6), lowering the blood pressure of mammals (8) and antiinflammatory activity 0.5 times that of hydrocortisone (11). Aminothiazoles of the structure VIII, have also showed antiinflammatory activity (14). 2'-Aminothiazolo[3,2-*d*]-5 α -cholest-2-ene (V) and 2'-aminothiazolo[17,16-*d*]androst-5,16-dien-3 β -ol acetate (XX, $\text{R} = \text{NH}_2$) were tested for antimicrobial activity (12).

The cholestan-aminothiazole had no antimicrobial activity against any of the organisms which were tested, while androsten-aminothiazole showed moderate activity. The microorganisms used and the doses for testing are reported below.

Organism	Compound (a)	
	V	XX ($\text{R} = \text{NH}_2$)
<i>Escherichia coli</i>	NI	NI
<i>Pseudomonas aeruginosa</i>	NI	NI
<i>Streptococcus ugalactiae</i>	NI	250
<i>Streptococcus mutans</i>	NI	62.5
<i>Streptococcus aureus</i>	NI	NI
<i>Corynebacterium sp.</i>	1000	62.5
<i>Nocardia asteroides</i>	NI	125
<i>Candida albicans</i>	NI	250
<i>Saccharomyces arevisiae</i>	NI	625

(a) NI stands for not inhibitory at 1000 mg/ml; dilutions tested (mg/ml) 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.8125.

Compounds of the structure XI are useful as anabolic-androgenic agents (15).

Steroido[12,11-*d*]thiazoles (XVII) produce antigestagenic activity (18).

2'-Substituted thiazolo[17,16-*d*]steroids of the androstanes used as controlling agents for menopausal illnesses, progesterone antagonists, and for hypergonadism control (22-23).

The 3-methoxy-2'-aminothiazolo[17,16-*d*]estra-1,3,5(10),16-tetraene has an important inhibiting action on the hypophysis and is particularly effective for the treatment of the hypophysis overloaded with FSH, caused by castration or menopause (24).

The 17β -(2-substituted-4-thiazolyl)-4-androsten-3-one series (XXX, XXXVIII-XXXIX) have a digitalis-like regulating effect on cardiac arrhythmia and also have hypotensive and pituitary-inhibitory properties (25). In opposite, Shaub and Weiss (26) have reported that in 17β -(2-amino-4-thiazolyl)-4-androsten-3-one derivatives, no activity of significant interest was observed.

However, Japanese workers (27-29, 31-33) have studied the pharmacological properties of 17β -[2-alkylamino- (or 2-arylamino- or 2-*N,N*-alkylarylamino-) thiazolyl]androst-4-en-3 β ,17 α -diol and 17β -[2-alkylamino- (or 2-arylamino- or 2-*N,N*-alkylarylamino-) 4-thiazolyl]androst-4-en-3-one derivatives and found that some of these have digitalis-like properties.

The analogue 17β -(2'-amino-4'-thiazolyl)-5 β ,14 β -androstane-3 β ,14-diol 3-acetate hydrochloride (XXXII) showed no inotropic activity (30).

The ternorcholanylthiazoles (XLII-XLIII) are useful because of their regulatory effect on the cardiovascular system and their antihormonal activity. They act as anti-hypotensive agents (34).


Steroidal thiazolines of the structure LI have showed, anabolic activity (37).

The attempts, so far recorded, to synthesize steroido-[3,4-*d*]-[2'-imino-3'-substituted] thiazolines (LXXVIII) exhibiting contraceptive and antilipogenic activity have met with success, and their quaternary salts (LXXX) possessed antibacterial activity (42).

Steroido-thiazolidine CXXXIIIb was found to possess c-AMP phosphodiesterase inhibitory properties in a minimum inhibitory concentration of 50 mg/ml when tested in vitro by a maximal dose of 100 mg/ml (58).

3 β -Acetoxy-3'-methylisothiazolo[17,16-*d*]androst-5,16-diene (CXLI) is an anti-corpus luteum substance (65).

Transient pro-drug forms of androstane CL, 4,5-didehydro CL, and 1,2,4,5-tetrahydro CL ($\text{R}_3, \text{R}_4 = \text{H}$, alkyl, $\text{R}_3\text{R}_4 = \text{CR}_7\text{R}_8$, $\text{R}_7\text{R}_8 = \text{alkyl}$, aryl, cycloalkyl, $\text{R}_5 = \text{OH}$, $\text{R}_6 = \text{H}$, $\text{R}_5\text{R}_6 = \text{O}$) were useful in alleviating inflammatory conditions. Compounds CL also were suitable for



topical or oral administration and were efficiently metabolized by the skin or by the gastrointestinal wall in a non-toxic fashion (66).

REFERENCES AND NOTES

- (1) H. J. Ringold, C. Djerassi and J. A. Zderic, U. S. Patent, 3,080,359 (1963); *Chem. Abstr.*, **59**, 11609 (1963).
- (2) N. J. Doorenbos and C. P. Dorn, Jr., *J. Pharm. Sci.*, **50**, 271 (1961).
- (3) N. J. Doorenbos and C. P. Dorn, Jr., *ibid.*, **51**, 414 (1962).
- (4) J. A. Zderic, O. Halpern, H. Carpio, A. Ruiz, D. C. Limon, L. Magana, H. Ziménej, A. Bowers and H. J. Ringold, *Chem. Ind.*, 1625 (1960).
- (5) J. A. Zderic, H. Carpio, A. Ruiz, D. C. Limon, F. Kincl and H. J. Ringold, *J. Med. Chem.*, **6**, 195 (1963).
- (6) P. G. Holton and E. Necochea, *J. Med. Pharm. Chem.*, **5**, 1352 (1962).
- (7) H. Antaki and V. Petrow, *J. Chem. Soc.*, 901 (1951).
- (8) R. O. Clinton, U. S. Patent, 3,081,228 (1963); *Chem. Abstr.*, **59**, 5235 (1963).
- (9) J. M. Kramer, K. Brückner, K. Irmscher and K. H. Bork, *Chem. Ber.*, **96**, 2803 (1963).
- (10) J. Korman, U. S. Patent, 2,813,859 (1957); *Chem. Abstr.*, **52**, 5492 (1958).
- (11) H. Mroziak, P. Bukhschaher, J. Hannah and J. H. Fried, *J. Med. Chem.*, **7**, 584 (1964).
- (12) P. Catsoulacos and D. Kallias, *J. Heterocyclic Chem.*, **16**, 763 (1979).
- (13) V. I. Dénes and G. Ciurdu, *Chem. Commun.*, 621 (1969).
- (14) A. G. Schering, German Patent, 1,169,442 (1964); *Chem. Abstr.*, **61**, 3175 (1964).
- (15) A. Bowers and J. Edwards, U. S. Patent, 3,076,801 (1963); *Chem. Abstr.*, **59**, 12874 (1963).
- (16) N. J. Doorenbos and A. P. Shroff, *Steroids*, **5** 399 (1965).
- (17) J. Kawanami, U. S. Patent, 3,168,516 (1965); *Chem. Abstr.*, **62**, 9208d (1965).
- (18) T. Yoneno, Japanese Patent, 12,924 (1963); *Chem. Abstr.*, **60**, 640 (1964).
- (19) K. Takeda and T. Komeno, *Chem. Pharm. Bull.*, **8**, 468 (1960).
- (20) K. Takeda and T. Komeno, *ibid.*, **10**, 1173 (1962).
- (21) T. Komeno, Japanese Patent, 26,404 (64) (1961); *Chem. Abstr.*, **62**, 10486 (1965).
- (22) T. Yoneno, U. S. Patent, 3,119,816 (1964); *Chem. Abstr.*, **60**, 10757 (1964).
- (23) T. Komeno, French M., 6235 (1963); *Chem. Abstr.*, **74**, 142182n (1971).
- (24) Roussel-UCLAF, Netherlands, Appl. 6,610,322 (1967); *Chem. Abstr.*, **68**, 3117h (1968).
- (25) J. W. Ralls and C. G. Bergstrom, U. S. Patent, 2,793,207 (1957); *Chem. Abstr.*, **52**, 464 (1958).
- (26) R. E. Schaub and M. J. Weiss, *J. Org. Chem.*, **26**, 1223 (1961).
- (27) K. Takamura, C. Isono, S. Takaku and Y. Nitta, *Chem. Pharm. Bull.*, **11**, 604 (1963).
- (28) K. Takamura and S. Takama, Japanese Patent, 22,282(63) (1961); *Chem. Abstr.*, **60**, 3058 (1964).
- (29) K. Takamura and S. Takahisa, Japanese Patent, 18,690(63) (1960); *Chem. Abstr.*, **60**, 4217 (1964).
- (30) M. E. Wolff, H. H. Chang and W. Ho, *J. Med. Chem.*, **13**, 657 (1970).
- (31) K. Takamura, C. Isono, S. Takama and Y. Nitta, *Chem. Pharm. Bull.*, **11**, 613 (1963).
- (32) K. Takamura and S. Takahisa, Japanese Patent, 18,691(63) (1960); *Chem. Abstr.*, **60**, 4217 (1964).
- (33) K. Takamura and S. Takama, Japanese Patent, 22,578(63) (1961); *Chem. Abstr.*, **60**, 4214 (1964).
- (34) R. M. Dodson, U. S. Patent, 2,705,232 (1955); *Chem. Abstr.*, **50**, 5793 (1956).
- (35) F. Hodosan and A. Balogh, *Rev. Roum. Chim.*, **11**, 383 (1966).
- (36) T. Yoneno, French 1,360,436 (1964); *Chem. Abstr.*, **60** 10746b (1964).
- (37) M. Hirakura, M. Watanabe and E. Kaneko, Japanese Patent, 70,09,536 (1970); *Chem. Abstr.*, **73**, 15114w (1970).
- (38) K. Takeda, T. Komeno, J. Kawanami, S. Ishihara, H. Kadokawa, H. Tokura and H. Itani, *Tetrahedron*, **21**, 329 (1965).
- (39) M. M. Campbell and R. C. Craig, *J. Chem. Soc., Perkin Trans. I*, 766 (1980).
- (40) R. C. Cambie, H. H. Lee, P. S. Rutledge and P. D. Woodgate, *ibid.*, 765 (1979).
- (41) B. Schoenecker and K. Ponsold, German Patent (East), 76,015 (1970); *Chem. Abstr.*, **75** 118478p (1971).
- (42) T. L. Popper, U. S. Patent, 3,772, 283 (1973); *Chem. Abstr.*, **80**, 37391f (1974).
- (43) K. Takeda, T. Komeno, S. Ishihara and H. Itani, *Chem. Pharm. Bull.*, **14**, 1096 (1966).
- (44) T. Yoneno, Japanese Patent, 69,27,804 (1969); *Chem. Abstr.*, **72**, 32146e (1970).
- (45) I. Kitagawa, Y. Ueda, T. Kawasaki and E. Mosestigg, *J. Org. Chem.*, **28**, 2228 (1963).
- (46) I. Kitagawa and Y. Sato, *J. Org. Chem.*, **29**, 339 (1964).
- (47) K. Ponsold and B. Schoenecker, German Patent (East), 64,716 (1968); *Chem. Abstr.*, **71**, 50381m (1969).
- (48) D. Calsines, A. V. Kamernitskii and A. M. Turuta, *Izv. Akad. Nauk, SSSR, Ser. Khim.*, 1841 (1976).
- (49) A. V. Kamernitskii, A. M. Turuta, T. M. Fadeeva and V. A. Pavlov, *ibid.*, 881 (1979).
- (50) A. V. Kamernitskii, D. Calsines and A. M. Turuta, *ibid.*, 2090 (1977).
- (51) K. Ponsold and W. Preibsch, *Chem. Ber.*, **104**, 1752 (1971).
- (52) K. Ponsold and W. Ihn, *Tetrahedron Letters*, 4121 (1972).
- (53) A. V. Kamernitskii, A. M. Turuta, T. M. Fadeeva and D. Calsines, *Synthesis*, 592 (1979).
- (54) G. Drefahl and M. Huebner, *J. Prakt. Chem.*, **23**, 149 (1964).
- (55) C. Djerassi, N. Crossley and M. A. Kielezewski, *J. Org. Chem.*, **27**, 1112 (1962).
- (56) S. Lieberman, *Experientia*, 411 (1946).
- (57) S. Lieberman, P. Brazeau and L. B. Hariton, *J. Am. Chem. Soc.*, **70**, 3094 (1948).
- (58) Y. Golander, E. Breuer and S. Sarel, *Arch. Pharm.*, **312**, 192 (1979).
- (59) Z. Paryzek and M. Kielezewski, *Bull. Acad. Pol. Sci., Ser. Sci. Chim.*, **23**, 91 (1975).
- (60) Z. Paryzek and M. Kielezewski, *ibid.*, **23**, 191 (1975).
- (61) Z. Paryzek and M. Kielezewski, *ibid.*, **23**, 405 (1975).
- (62) H. Singh, r. B. Mathur, N. J. Doorenbos, A. K. Bose and S. D. Sharma *Tetrahedron* **27**, 3993 (1971).
- (63) P. M. Irismetov, V. V. Kuril'skaya and I. M. Goryaev, *Izv. Acad. Nauk Kaz. SSSR, Ser. Khim.*, **26**, 41 (1976).
- (64) T. Komeno, *Chem. Pharm. Bull.*, **8**, 680 (1960).
- (65) T. Yoneno, Japanese Patent, 15,135 (1964); *Chem. Abstr.*, **61**, 16128 (1964).
- (66) N. S. Bodor and K. B. Sloam, U. S. Patent, 4,069,322 (1978); *Chem. Abstr.*, **89**, 75419q (1978).